






Objective. To review demographic and procedural factors and their association with weaning rate and survival from 
extracorporeal membrane oxygenation (ECMO) in pediatric patients undergoing repair of cardiac malformations.  
Methods. The hospital records of children requiring ECMO during cardiac operation due to failure to wean from cardio-
pulmonary by pass (CPB) were retrospectively reviewed, and an analysis of variables affecting survival was performed.  
Results. Thirty-five pediatric patients between January 1, 2000 and December 31, 2006 required ECMO for cardiopulmonary 
support during cardiac operations.  ECMO survival was 54.3% and was comparable across all age groups.  The lowest pH 
during ECMO treatment was the only predictor of mortality (P = 0.006). No other patient, surgical or anesthetic, factor was 
associated with either weaning from ECMO or hospital survival.  
Conclusions.  No clear risk factor could be identified for survival from ECMO in our pediatric patients who underwent cardiac 
surgery and failed weaning from cardiopulmonary bypass. 
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Introduction
Extensive repairs of complex cardiac 
anomalies utilizing cardiopulmonary 
bypass (CPB) may result in severe 
myocardial dysfunction leading to 
inability to wean pediatric patient from 
CPB. (1) Occasionally this complica-
tion may be refractory even to the most 
intensive pharmacologic therapy and 
the use of extracorporeal membrane 
oxygenator (ECMO) may be the only 
alternative. A significant body of litera-
ture exists regarding the use of ECMO 
in postoperative course after cardiac 
surgery in children, (2-5) and more lim-
ited information exists regarding the 
use of intraoperative ECMO. In present 
study we report outcome in 35 pediat-
ric patients who received ECMO intra-
operatively after failing weaning from 
CPB following repair of complex heart 
malformations.  Incidence and surviv-
al analysis of this patient population 
was recently described. (6) In present 
report we expand the analysis to exam-
ine association between demographic, 
co-morbid, and procedural factors in 
these patients and failure to wean from 
surgical ECMO or hospital survival.  
Methods
Study Design, Patients and Setting. 
After Mayo Clinic Institutional Review 
Board (Rochester, MN, USA) approval, 
we ascertained all patients 0-17 years 
of age who were treated with ECMO 
during cardiac operations requiring 
CPB at Mayo Clinic, Rochester, MN, 
between January 1, 2000 and Decem-
ber 31, 2006.  All identified charts were 
authorized for review by the Institutional 
Review Board.  Cases were identified 
from the Mayo Clinic ECMO registry. 
We reviewed only medical records of 
children who were treated with ECMO 
during their index cardiac surgery.  Suc-
cessful weaning from ECMO was con-
sidered if the child survived at least 48 
hours after separation.  
Data collection and analysis. The medi-
cal records of all index patients were 
abstracted. The primary objective was 
to examine the potential risk factors for 
failure to wean from ECMO in pediatric 
patients undergoing repair of cardiac 
malformations. We analyzed patient 
demographics (age, gender, American 
Society of Anesthesiologists Physical 
Status [ASA PS] score), patient-related 
factors: surgical urgency status, and 
dominant cardiac anatomy, univen-
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tricular physiology (encompasses a 
wide variety of heart defects that func-
tionally and physiologically constitute 
a single ventricular chamber) (7,8) or 
biventricular heart physiology. Finally, 
we analyzed the following procedural 
factors: use of circulatory arrest, use 
of intraoperative ultrafiltration, con-
tinuous veno-venous hemofiltration 
(CVVHF), requirement for other means 
of mechanical circulatory support 
(intraaortic balloon pump [IAB], left ven-
tricular assist device [LVAD]), duration 
of anesthesia before ECMO, duration 
of CPB, and completeness of surgical 
repair (complete vs. incomplete repair). 
The variables assessed while on-ECMO 
included: duration of ECMO therapy, 
and highest creatinine, and lowest pH 
during ECMO treatment.   
Statistical Analysis. The bivariate asso-
ciation between each of the candidate 
risk factors and weaning success and 
hospital survival was first evaluated 
using the rank sum test for continu-
ous variables and Fisher’s exact test 
for categorical variables. Duration of 
anesthesia before ECMO, duration of 
CPB, duration of ECMO therapy, high-
est creatinine level while on ECMO and 
lowest pH value while on ECMO were 
analyzed as continuous variables, while 
all other variables were analyzed as 
categorical variables. In all cases, two-
tailed P-values ≤ 0.05 were considered 
statistically significant. Analyses were 
performed using SAS statistical soft-
ware (Version 8.2; SAS Institute, Inc., 
Cary, NC, USA).  
Results
Between January 1, 2000 and Decem-
ber 31, 2006 35 pediatric patients failed 
weaning from CPB and received ECMO 
intraoperatively. Table 1 shows demo-
graphics, primary diagnosis, surgical 
details and outcome of our ECMO 
patients. Table 2 shows association 
between demographic, patient and 
procedural characteristics (all categori-
cal variables) and ability to be weaned 
from ECMO (n=24) as well as hospi-
tal survival (P values in table 2 com-
pare those who were “able to wean” 
vs. “unable to wean”, and “survived 
vs. died”). None of the tested charac-
teristics were significantly associated 
with weaning success or survival. The 
frequency of successful weaning from 
ECMO was 68.6% (24/35), however 
subsequently 5 patients died from other 
postoperative complications (cardiac 
arrest, malignant dysrhythmias, etc), 
and the overall survival rate was 54.3%. 
All 5 deaths occurred greater than 48 
hours after separation from ECMO.  
From exploratory analyses, no patient 
or procedural characteristics were 
found to differ significantly between 
patients who were successfully weaned 
from ECMO vs. not.  Furthermore, none 
of the tested characteristics were dif-
ferent between the survivors and non-
survivors. However, there was a trend 
toward better survival for patients who 
received either ultrafiltration or hemofil-
tration during surgery (P = 0.063).  Table 
3 shows association between patient 
and procedural (continuous) variables 
and weaning success and hospital sur-
vival. None of the tested variables was 
associated with weaning success, and 
only one, the lowest pH while on ECMO, 
was associated with worse hospital sur-
vival (P=0.006). While the duration of 
ECMO in those who were successfully 
weaned tended to be shorter (61 vs. 
106 hours) this difference did not reach 
statistical significance (tested using 
the rank sum to account for outliers). 
Among our ECMO patients, 9 required 
surgical reexploration for bleeding, 4 
had intracranial hemorrhage, 1 intrac-
ranial thromboembolic event, while 3 
received orthotropic heart allotrans-
plant (1 as a primary procedure, and 2 
following failed index surgery).  
Discussion
Inability to regain cardiopulmonary 
function to sustain life, regardless of 
maximal pharmacologic support, is one 
of the most significant complications of 
surgery for congenital heart malforma-
tions. A mechanical cardiopulmonary 
support via ECMO has been increas-
ingly used in our institution for pediatric 
patients with post-CPB refractory heart 
failure. At Mayo Clinic the decision to 
institute the ECMO is always made by 
cardiovascular surgeon and typically 
when inotropic support of epinephrine 
exceeds 0.15 mcg/kg/min, when one 
or more following conditions exist: 
systemic ventricular dysfunction with 
elevated filling pressures (right atrial 
pressure (RAP) >20 mmHg, left atrial 
pressure (LAP) >15 mmHg), difficulty 
with oxygenation and/or ventilation, 
pulmonary hypertension with right ven-
tricular dysfunction.  
We recently reported survival of 35 
children who received ECMO for phar-
macologically refractory heart failure 
during repair of congenital heart mal-
formations. (6)  Over half of our children 
(54.3%) requiring ECMO were neonates 
followed by infants (22.3%). The wean-
ing rate from ECMO was 68.7%, and 
the hospital survival was 54.3% which 
is the range reported by others. (5,9,10) 
The small number of children in present 
study does not allow for comprehensive 
analysis of risk factors. Therefore, we 
conducted only an exploratory analysis 
which did not identify any demographic 
or procedural characteristics associat-
ed with outcome including age, gender, 
ASA PS, primary cardiac physiology 
(univentricular vs. biventricular), type of 
repair (complete vs. incomplete), use 
of circulatory arrest, intraoperative use 
of ultrafiltration or need for preoperative 
ventricular assist (left ventricular assist 
device or intra-aortic balloon pump), 
and shorter anesthetic course before 
initiation of ECMO. Only one factor, 
the lowest pH during ECMO treatment, 
was associated with worse hospital 
survival.  
In other ECMO studies several pre-
dictors of mortality have been identi-
fied, albeit majority of predictors were 
associated with complications that 
occurred in later postoperative course. 
For example, Morris et al. (11) identified 
kidney or hepatic failure, and Mont-
gomery et al. (12) the presence of mul-
tiple organ dysfunction and infections 
during ECMO treatment as predictors 
of survival.  However, these are not con-
sistent findings, as another study failed 
to establish association between the 
degree of renal dysfunction or infection 
and survival. (13) The only predictor of 
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Table 1. Patients who failed separation from cardiopulmonary bypass (CPB) received intraoperative extracorporeal 
membrane oxygenation (ECMO) and survived to leave the operating room.  







2000 5d/F/3 IAA Type A; VSD, ASD 
Complete repair, closure of ASD and 
VSD, and end-to-end aortoplasty between 
descending aorta and aortic arch. 
No No
2000 17m/M/4
Ebstein’s anomaly, PFO, severe TR, atrial 
flutter
TV replaced, PFO closed, cryoablation 
right atrial isthmus
Yes Yes
2000 20m/M/3 TGA, tricuspidal atresia, subaortic stenosis Relief subaortic stenosis No No.
2000 3m/F/4
Anomalous left CA from PA; severe LV 
dysfunction 
Repair of anomalous CA, CABG No No
2001 10d/F/3 Complete TGA ASO Yes No
2001 17y/M/4 TV atresia, failing Fontain circulation
Intraatrial conduit, Right Maze procedure, 




Pulmonary atresia, VSD, previous Blalock-
Taussig shunt
Complete repair Yes Yes
2001 6d/M/4
Unbalanced complete AVSD; hypoplastic 
LV, IAA Type B
Modified Norwood; repair VSD and IAA Yes Yes





TOF, complete ASD, severe regurgitation 
common AV valve
Complete repair DORV/AV canal (AVSD) 
defect; residual LVOT-repaired in second 
operation
No No
2002 3d/M/4 TGA, IVS ASO Yes Yes
2002 12y/M/4E Prosthetic MV and AV endocarditis MV & AV replacement, CABG x1 Yes Yes
2002 3d/M/3 TGA, PDA, IVS, ASD ASO  No
2002 48d/F/4E Hypoplastic left heart Heart transplant; aortic arch reconstruction Yes Yes
2003 14d/F/4 Double outlet R ventricle, VSD, AS Modified Norwood procedure Yes Yes
2003 5d/M/3 IAA Type A, CoA, ASD, VSD,PI Arch reconstruction, ASD+VSD closure  No
2003 2d/M/4 HLHS, ASD Norwood procedure, stage I Yes Yes
2003 3m/F/3 Complete AVSD; Down syndrome Complete repair Yes No
2003 7d/M/4
Truncus arteriosus, severe truncal valve 
insufficiency
Complete repair Yes Yes
2003 3d/M/4 TGA, VSD, DORV ASO, VSD repair, PDA ligation No No
2003 1d/M/5E Obstructive TAPVC, PDA Complete repair, ligation PDA Yes Yes
2004 6d/M/4
Obstructive TAPVC (infracardiac). PDA, 
pulmonary edema
Complete repair TAPVC, ligation of PDA No No
2004 40d/M/3 Pulmonary atresia, VSD, PDA Compete repair, ligation PDA Yes Yes
2004 5y/F/4E
Ebstein’s anomaly, ASD, severe RV 
dysfunction
TVR, ASD closure, bidirectional Glenn 
shunt; Converted to fenestrated Fontain
No No.
2004 6d/M/4 HLHS, AVSD
Norwood procedure, pulmonary homograft, 
reconstruction RV, PDA closure
No No
2005 7y/F/4 Cleft MV, MVR, TVR, CHF MV, TV repair Yes Yes
2005 4d/F/4 CoA, hypoplastic arch, large PDA, PFO Repair of CoA, ligation PDA Yes Yes
2005 7d/M/3
TGA, VSD, ASD, bicuspidal pulmonary 
valve
ASO, VSD+ASD closure Yes Yes
2005 11y/M/3 Congenital AS AVR Yes Yes
2005 4d/M/4 Congenital AS Ross-Konno aortoventriculoplasty Yes No
2006 21d/F/3 Obstructive TAPVC Compete repair Yes Yes
2006 21d/F/3
AVSD, 2 AV valve orifices, large ostium 
primum defect, VSD, hypoplastic L 
ventricle
Biventricular repair Yes Yes
2006 19d/F/3
Unbalanced AVSD; HLHS and aortic arch; 
coarctation aorta. 
Modified Norwood, stage 1 No No
2006 25d/M/4 Obstructive TAPVS; PHTN Complete repair Yes Yes
2006 3m/F/4
Interrupted aortic arch; severe subaortic 
stenosis, severe valvular stenosis, VSD
Complete repair; Heart transplantation 
(second operation);acute allograft rejection
No No
AR, aortic regurgitation; ARF, acute renal failure; AS, aortic stenosis; ASA, American Society of Anesthesiologists; ASD, atrial septa defect; ASO, arterial switch 
operation; AV, atrio-ventricular; AVR, aortic valve replacement; AVSD, atrioventricular septal defect (AV canal); BV, biventricular; CA coronary artery; CABG, 
coronary artery bypass grafting; CoA, coarctation of the aorta; CHF, congestive heart failure; d, day; DORV, double outlet right ventricle; E, emergency; ECMO, 
extracorporeal membrane oxygenation; F, female; HLHS, hypoplastic left heart syndrome; IAA, interrupted aortic arch; IVS, intact ventricular septum; LV, left 
ventricular; LVOT, left venticular outflow tract; m, month; M, male; MS, mitral stenosis; MV, mitral valve; MVR, mitral valve regurgitation; PA, pulmonary artery; 
PDA, patent ductus arteriosus; PFO, patent foramen ovale; PHTN, pulmonary hypertension; PI, pulmonary insufficiency;  RV, right ventricle; S/P, status post; 
TAPVC, total anomalous pulmonary venous connection; TGA, transposition of great arteries; TOF, tetralogy of Fallot; TR, tricuspidal regurgitation; TV,  tricuspidal 
valve; TVR, tricuspidal valve regurgitation; VSD, ventricular septal defect. RACHS-1 risk for in-hospital death, see classification in Jenkins et al. (16)
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mortality in our study was the lowest pH 
value while on ECMO, which is consist-
ent with a study (13) that showed that 
the highest lactate level within 48 hours 
on ECMO predicted death.  
Table 2.  Bivariate association between patient and procedural characteristics and ability to be weaned from extracor-








Overall 35 24 (68.6) 19 (54.3)
Gender 0.708 0.503
Male 22 16 (72.7) 13 (59.1)
Female 13 8 (61.5) 6 (46.2)
ASA PS 0.733 0.562
3 12 9 (75.0) 5 (41.7)
4 21 14 (66.7) 13 (61.9)
















Heart physiology 0.226 1.000
Univentricular 8 4 (50) 4 (50)
Biventricular 27 20 (74.1) 15 (55.6)
Surgical repair 0.226 1.000
Incomplete 8 4 (50) 4 (50)
Complete 27 20 (74.1) 15 (55.6)
Emergency 0.640 0.187
No 29 19 (65.5) 14 (48.3)
Yes 6 5 (83.3) 5 (83.3)
Stable at arrival to OR‡ 1.000 0.503
No 13 9 (69.2) 6 (46.2)
Yes 22 15 (68.2) 13 (59.1)
Circulatory Arrest 1.000 0.723
No 10 7 (70.0) 6 (60)
Yes 25 17 (68.0) 13 (52)
Intraoperative use of UF/HF (any) 0.063 0.379
No 6 2 (33.3) 2 (33.3)
Yes 29 22 (75.9) 17 (58.6)
LVAD or IABP on arrival to OR 0.314 0.457
No 34 24 (70.6) 19 (55.9)
Yes 1 0 (0.0) 0 (0)
*Overall number in each category used as the denominator when calculating the percentage of patients able to wean from ECMO.
†P-values are from Fisher’s exact. 
‡Patients were considered unstable if they required either mechanical ventilation or vasopressor support on arrival to the operating room (OR).
Abbreviations:  UF/HF-ultrafiltration or hemofiltration; American Society of Anesthesiologists Physical Status (ASA PS); LVAD, left ventricular assist device; IABP, 
intraaortic balloon pump.
Intuitively, the type of heart defect or 
completeness of surgical repair could 
affect the survival. For example, Black 
et al. (14) found better ECMO survival 
in children who had complete repair 
than in those with residual heart defect 
(incomplete repair). However, the com-
pleteness of repair was not a significant 
factor for either ECMO weaning or sur-
vival in our patients.  Kolovos et al. (13) 
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reported that children who received 
ECMO after an adequate two-ventricu-
lar repair (biventricular physiology) had 
lower risk of death compared to those 
with single ventricle physiology.  In con-
trast, another study reported 61% sur-
vival to discharge in infants with univen-
tricular physiology, compared with 43% 
in those with biventricular physiology. 
(9) Morris et al. (11) did not confirm the 
association of univentricular physiology 
with increased mortality, which agrees 
with our findings (table 2).  
Generally speaking, longer organ 
ischemia and/or time on bypass, use 
of circulatory arrest, are all surrogate 
markers of increased complexity of 
repair, and therefore could be associ-
ated with mortality. However, none of 
these factors played a significant role in 
weaning from ECMO or hospital survival 
in our patients.  Another surrogate index 
of less reversible organ dysfunction is 
extended time spent on ECMO (14), and 
its use for more than 72 hours has been 
related with poor outcome. (9) Others 
reported no survival after use of ECMO 
more than 208 (15) or 256 hours. (12) 
While our non-survivors spent longer 
time on ECMO (ECMO times were 60.5 
vs. 106 hours, for survivors vs. non-sur-
vivors, respectively) the difference was 
not statistically significant. In contrast 
to some reports (12,14,15), Morris et al. 
(11) found that ECMO duration over 72 
hours is not necessarily the predictor of 
poor prognosis. Therefore, protracted 
use of ECMO appears not to be a clear 
indication for its discontinuation.  
Study Limitations.  The limitations of this 
study are the small number of ECMO 
cases which precludes the perform-
Table 3.  Bivariate association between procedural characteristics (continuous variables) and ability to be weaned from 
















Anesthesia time before   
ECMO (hr)
7.5 (4.3, 9.4) 6.5 (4.0, 10.5) 0.099 7.5 (4.1, 9.4) 6.6 (4.0, 10.5) 0.191
Duration of CPB (min) 256 (87, 433) 189.5 (99, 401) 0.140 233 (87, 433) 191 (105, 401) 0.778
Time of ECMO (hr) 106 (4, 1261) 60.5 (19, 171) 0.126 100.5 (4, 1261) 57 (20, 171) 0.132
Highest creatinine on ECMO 0.8 (0.5, 2.7) 0.75 (0.3, 2.4) 0.421 0.85 (0.3, 2.7) 0.7 (0.4, 2.4) 0.309
Lowest pH on ECMO 7.32 (7.14, 7.36) 7.35 (7.14, 7.49) 0.105 7.32 (7.14, 7.36) 7.36 (7.15, 7.49) 0.006
†P-values are from the rank-sum test.
Values are median (min-max).
ance of meaningful statistical analyses 
of risk factors associated with wean-
ing and mortality. The retrospective 
nature of our review carries the inherent 
limitation of the potentially inconsistent 
nature of information in the medical 
record. We cannot exclude that rel-
evant information was omitted from the 
description of some events.  
In conclusion, in pediatric patient who 
require intraoperative ECMO following 
CPB hospital survival was 54.3%. We 
identified association between lowest 
pH during ECMO treatment and survival 
and no other demographic or proce-
dural factors were associated with either 
weaning from ECMO or hospital survival. 
Therefore, it appears that the complexity 
of repair and surgical factors related to 
complex heart anomalies determined 
the outcome in our patient cohort.
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